{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:16:14Z","timestamp":1788441374874,"version":"build-2803163510"},"reference-count":79,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Fungal esophagitis, predominantly caused by Candida species, remains the leading form of infectious esophagitis worldwide. Although historically linked to human immunodeficiency virus infection, its epidemiology has shifted over recent decades, with a growing incidence among oncology patients receiving immune checkpoint inhibitors, individuals with eosinophilic esophagitis on oral corticosteroids, and solid-organ transplant recipients. Increasing evidence highlights that disease pathogenesis extends beyond simple fungal overgrowth and involves intricate host\u2013pathogen interactions. Pathogenic mechanisms such as adhesion, hyphal transition, and biofilm formation enhance fungal virulence, while mucosal immune dysfunction, particularly impaired T helper 17\/interleukin 17 signaling and reduced antimicrobial peptide activity, predisposes to persistent infection. Antifungal resistance represents an emerging challenge, driven by efflux pump overexpression, ERG11 mutations conferring azole resistance, and mutations of FKS genes leading to reduced echinocandin susceptibility. These molecular mechanisms underscore the complexity of treatment and have important implications for antifungal selection and clinical management. While fluconazole remains the first-line agent for most cases, the increasing prevalence of non-albicans Candida species and drug resistance underscore the importance of alternative medications with different molecular targets. Agents such as the recently approved rezafungin as well as compounds such as ibrexafungerp and fosmanogepix, represent promising options for the treatment of refractory disease. This review synthesizes current advances in the molecular pathogenesis of fungal esophagitis, with particular emphasis on host\u2013fungal interactions, antifungal resistance mechanisms, and novel treatment strategies. A deeper understanding of these processes is essential to improve management and to guide the development of innovative immunomodulatory and antifungal therapies.<\/jats:p>","DOI":"10.31083\/fbl50241","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:35:31Z","timestamp":1788438931000},"source":"Crossref","is-referenced-by-count":0,"title":["Fungal Esophagitis: Molecular Insights Into Pathogenesis and Emerging Antifungal Strategies"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1914-150X","authenticated-orcid":true,"given":"Konstantinos","family":"Papantoniou","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7790-7845","authenticated-orcid":true,"given":"Ploutarchos","family":"Pastras","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4489-1485","authenticated-orcid":true,"given":"Ioanna","family":"Aggeletopoulou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-8209","authenticated-orcid":true,"given":"Christos","family":"Triantos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kim NY, Lee J. Infective Esophagitis. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 2025; 25: 108\u2013116.","DOI":"10.7704\/kjhugr.2025.0007"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Vazquez JA. Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV\/AIDS (Auckland, N.Z.). 2010; 2: 89\u2013101.","DOI":"10.2147\/hiv.s6660"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Takahashi Y, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, et al. Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients. PloS One. 2015; 10: e0133589.","DOI":"10.1371\/journal.pone.0133589"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mohamed AA, Lu XL, Mounmin FA. Diagnosis and Treatment of Esophageal Candidiasis: Current Updates. Canadian Journal of Gastroenterology & Hepatology. 2019; 2019: 3585136.","DOI":"10.1155\/2019\/3585136"},{"key":"ref5","unstructured":"Robertson KD, Nagra N, Mehta D. Esophageal Candidiasis. StatPearls Publishing LLC.: Treasure Island (FL). 2023."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2016; 62: e1\u2013e50.","DOI":"10.1093\/cid\/civ933"},{"key":"ref7","unstructured":"Wilcox CM. Overview of infectious esophagitis. Gastroenterology & Hepatology. 2013; 9: 517\u2013519."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Hoversten P, Kamboj AK, Katzka DA. Infections of the esophagus: an update on risk factors, diagnosis, and management. Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus. 2018; 31.","DOI":"10.1093\/dote\/doy094"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Kimchy AV, Ahmad AI, Tully L, Lester C, Sanghavi K, Jennings JJ. Prevalence and clinical risk factors for esophageal candidiasis in non-human immunodeficiency virus patients: A multicenter retrospective case-control study. World Journal of Gastrointestinal Endoscopy. 2023; 15: 480\u2013490.","DOI":"10.4253\/wjge.v15.i6.480"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Gold JAW, Benedict K. Esophageal Candidiasis-Associated Hospitalizations: Declining Rates and Changes in Underlying Conditions, United States, 2010-2020. Open Forum Infectious Diseases. 2024; 11: ofae117.","DOI":"10.1093\/ofid\/ofae117"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Song S, Yang Y, Hu Q, Zhong R, Lei X, Wang C, et al. Infectious adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis based on FAERS database. Frontiers in Immunology. 2025; 16: 1647944.","DOI":"10.3389\/fimmu.2025.1647944"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Barchi A, Girelli M, Ventimiglia A, Mandarino FV, Danese S, Passaretti S, et al. Orally Dispersible Swallowed Topical Corticosteroids in Eosinophilic Esophagitis: A Paradigm Shift in the Management of Esophageal Inflammation. Pharmaceutics. 2025; 17: 1325.","DOI":"10.3390\/pharmaceutics17101325"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Silveira FP, Kusne S, AST Infectious Diseases Community of Practice. Candida infections in solid organ transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013; 13: 220\u2013227.","DOI":"10.1111\/ajt.12114"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Machado M, Fort\u00fan J, Mu\u00f1oz P. Invasive aspergillosis: A comprehensive review. Medicina Clinica. 2024; 163: 189\u2013198.","DOI":"10.1016\/j.medcli.2024.01.045"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Wilson A, Delport J, Ponich T. Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? International Journal of Microbiology. 2014; 2014: 371631.","DOI":"10.1155\/2014\/371631"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathogens. 2020; 16: e1008921.","DOI":"10.1371\/journal.ppat.1008921"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Tian L, Huang C, Fu W, Gao L, Mi N, Bai M, et al. Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Frontiers in Pharmacology. 2023; 14: 1217306.","DOI":"10.3389\/fphar.2023.1217306"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Ogiso H, Adachi S, Mabuchi M, Horibe Y, Ohno T, Suzuki Y, et al. Risk factors for the development of esophageal candidiasis among patients in community hospital. Scientific Reports. 2021; 11: 20663.","DOI":"10.1038\/s41598-021-00132-w"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Hoyer LL, Cota E. Candida albicans Agglutinin-Like Sequence (Als) Family Vignettes: A Review of Als Protein Structure and Function. Frontiers in Microbiology. 2016; 7: 280.","DOI":"10.3389\/fmicb.2016.00280"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Nobile CJ, Nett JE, Andes DR, Mitchell AP. Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryotic Cell. 2006; 5: 1604\u20131610.","DOI":"10.1128\/EC.00194-06"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Alonso-Monge R, Cort\u00e9s-Prieto I, Rom\u00e1n E, Pla J. Morphogenetic transitions in the adaptation of Candida albicans to the mammalian gut. Microbes and Infection. 2024; 26: 105253.","DOI":"10.1016\/j.micinf.2023.105253"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Alem MAS, Oteef MDY, Flowers TH, Douglas LJ. Production of tyrosol by Candida albicans biofilms and its role in quorum sensing and biofilm development. Eukaryotic Cell. 2006; 5: 1770\u20131779.","DOI":"10.1128\/EC.00219-06"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Sebaa S, Boucherit-Otmani Z, Courtois P. Effects of tyrosol and farnesol on Candida albicans biofilm. Molecular Medicine Reports. 2019; 19: 3201\u20133209.","DOI":"10.3892\/mmr.2019.9981"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Ramos-Pardo A, Castro-\u00c1lvarez R, Quind\u00f3s G, Eraso E, Sevillano E, Kaberdin VR. Assessing pH-dependent activities of virulence factors secreted by Candida albicans. MicrobiologyOpen. 2023; 12: e1342.","DOI":"10.1002\/mbo3.1342"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Zhou Y, Cheng L, Lei YL, Ren B, Zhou X. The Interactions Between Candida albicans and Mucosal Immunity. Frontiers in Microbiology. 2021; 12: 652725.","DOI":"10.3389\/fmicb.2021.652725"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Drummond RA, Dambuza IM, Vautier S, Taylor JA, Reid DM, Bain CC, et al. CD4(+) T-cell survival in the GI tract requires dectin-1 during fungal infection. Mucosal Immunology. 2016; 9: 492\u2013502.","DOI":"10.1038\/mi.2015.79"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Tangye SG, Puel A. The Th17\/IL-17 Axis and Host Defense Against Fungal Infections. The Journal of Allergy and Clinical Immunology. in Practice. 2023; 11: 1624\u20131634.","DOI":"10.1016\/j.jaip.2023.04.015"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Aggor FEY, Bertolini M, Coleman BM, Taylor TC, Ponde NO, Gaffen SL. Combinatorial actions of IL-22 and IL-17 drive optimal immunity to oral candidiasis through SPRRs. PLoS Pathogens. 2024; 20: e1012302.","DOI":"10.1371\/journal.ppat.1012302"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Bilal H, Khan MN, Khan S, Fang W, Chang W, Yin B, et al. Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management. Mycology. 2023; 15: 30\u201344.","DOI":"10.1080\/21501203.2023.2265664"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PloS One. 2011; 6: e17755.","DOI":"10.1371\/journal.pone.0017755"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Liu F, Fan X, Auclair S, Ferguson M, Sun J, Soong L, et al. Sequential Dysfunction and Progressive Depletion of Candida albicans-Specific CD4 T Cell Response in HIV-1 Infection. PLoS Pathogens. 2016; 12: e1005663.","DOI":"10.1371\/journal.ppat.1005663"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Chen YH, Jao TM, Shiue YL, Feng IJ, Hsu PI. Prevalence and risk factors for Candida esophagitis among human immunodeficiency virus-negative individuals. World Journal of Clinical Cases. 2022; 10: 10896\u201310905.","DOI":"10.12998\/wjcc.v10.i30.10896"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Sobue T, Bertolini M, Thompson A, Peterson DE, Diaz PI, Dongari-Bagtzoglou A. Chemotherapy-induced oral mucositis and associated infections in a novel organotypic model. Molecular Oral Microbiology. 2018; 33: 212\u2013223.","DOI":"10.1111\/omi.12214"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Armstrong AW, Blauvelt A, Mrowietz U, Strober B, Gisondi P, Merola JF, et al. A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. Dermatology and Therapy. 2022; 12: 787\u2013800.","DOI":"10.1007\/s13555-022-00687-0"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Papadakis M, Karniadakis I, Mazonakis N, Akinosoglou K, Tsioutis C, Spernovasilis N. Immune Checkpoint Inhibitors and Infection: What Is the Interplay? In Vivo (Athens, Greece). 2023; 37: 2409\u20132420.","DOI":"10.21873\/invivo.13346"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Niess JH, Kaymak T. Eosinophilic Esophagitis Pathogenesis: All Clear? Inflammatory Intestinal Diseases. 2025; 10: 135\u2013150.","DOI":"10.1159\/000546241"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Hoseinnejad A, Maheronnaghsh M, Taghizadeh Armaki M, Jafarzadeh J, Fatahinia M. Is there a difference in the expression levels of genes responsible for fluconazole resistance in Candida albicans isolated from people with different underlying diseases? A systematic review. Current Medical Mycology. 2025; 11: 1589.","DOI":"10.22034\/cmm.2025.345313.1589"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Li J, Aubry L, Brandalise D, Coste AT, Sanglard D, Lamoth F. Upc2-mediated mechanisms of azole resistance in Candida auris. Microbiology Spectrum. 2024; 12: e0352623.","DOI":"10.1128\/spectrum.03526-23"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Li Y, Hind C, Furner-Pardoe J, Sutton JM, Rahman KM. Understanding the mechanisms of resistance to azole antifungals in Candida species. JAC-antimicrobial Resistance. 2025; 7: dlaf106.","DOI":"10.1093\/jacamr\/dlaf106"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Tanwar S, Kalra S, Bari VK. Insights into the role of sterol metabolism in antifungal drug resistance: a mini-review. Frontiers in Microbiology. 2024; 15: 1409085.","DOI":"10.3389\/fmicb.2024.1409085"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Zajac C, Scott NE, Kline S, Erayil SE, Selmecki A. Hotspot gene conversion between FKS1 and FKS2 in echinocandin resistant Candida glabrata serial isolates. Npj Antimicrobials and Resistance. 2025; 3: 31.","DOI":"10.1038\/s44259-025-00102-6"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Elia\u0161 D, T\u00f3th Hervay N, \u010cern\u00e1kov\u00e1 L, Gbelsk\u00e1 Y. Changes in Ergosterol Biosynthesis Alter the Response to Cycloheximide, 4-Nitroquinoline-N-Oxide, Weak Organic Acids, and Virulence in Candida glabrata. Journal of Fungi (Basel, Switzerland). 2024; 10: 669.","DOI":"10.3390\/jof10100669"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Asayama N, Nagata N, Shimbo T, Nishimura S, Igari T, Akiyama J, et al. Relationship between clinical factors and severity of esophageal candidiasis according to Kodsi's classification. Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus. 2014; 27: 214\u2013219.","DOI":"10.1111\/dote.12102"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Baehr PH, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology. 1994; 106: 509\u2013532.","DOI":"10.1016\/0016-5085(94)90613-0"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Gaffar NR, Valand N, Venkatraman Girija U. Candidiasis: Insights into Virulence Factors, Complement Evasion and Antifungal Drug Resistance. Microorganisms. 2025; 13: 272.","DOI":"10.3390\/microorganisms13020272"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Nishimura S, Nagata N, Shimbo T, Asayama N, Akiyama J, Ohmagari N, et al. Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy. PloS One. 2013; 8: e58217.","DOI":"10.1371\/journal.pone.0058217"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Elhed A, Unutmaz D. Th17 cells and HIV infection. Current Opinion in HIV and AIDS. 2010; 5: 146\u2013150.","DOI":"10.1097\/COH.0b013e32833647a8"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed Research International. 2013; 2013: 204237.","DOI":"10.1155\/2013\/204237"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scandinavian Journal of Infectious Diseases. 1995; 27: 613\u2013617.","DOI":"10.3109\/00365549509047076"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Hirai T, Nashi M. Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective. Journal of Clinical Medicine. 2025; 14: 7537.","DOI":"10.3390\/jcm14217537"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Wilheim AB, Miranda-Filho DDB, Nogueira RA, R\u00eago RSDM, Lima KDM, Pereira LMMB. The resistance to fluconazole in patients with esophageal candidiasis. Arquivos De Gastroenterologia. 2009; 46: 32\u201337.","DOI":"10.1590\/s0004-28032009000100011"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Dai Y, Hu M, Guo S, Wu F, Han Y, Ni S, et al. Pharmacokinetic interaction between SHR2554 and fluconazole: A single-center, open-label and one-sequence crossover phase I trial in healthy Chinese subjects. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences. 2025; 212: 107163.","DOI":"10.1016\/j.ejps.2025.107163"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Szyma\u0144ski M, Chmielewska S, Czy\u017cewska U, Malinowska M, Tylicki A. Echinocandins - structure, mechanism of action and use in antifungal therapy. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022; 37: 876\u2013894.","DOI":"10.1080\/14756366.2022.2050224"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2004; 39: 770\u2013775.","DOI":"10.1086\/423378"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Alimentary Pharmacology & Therapeutics. 2004; 20: 475\u2013481.","DOI":"10.1111\/j.1365-2036.2004.02083.x"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Telbany A, Farfour H, Gomez K, Soliman Y, Kachaamy TA. Candida Esophagitis in Patients with Solid Organ Cancers. Journal of Clinical Medicine. 2026; 15: 1474.","DOI":"10.3390\/jcm15041474"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Annals of the New York Academy of Sciences. 2015; 1354: 1\u201311.","DOI":"10.1111\/nyas.12831"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Kristanc L, Bo\u017ei\u010d B, Jokhadar \u0160Z, Dolenc MS, Gomi\u0161\u010dek G. The pore-forming action of polyenes: From model membranes to living organisms. Biochimica et Biophysica Acta. Biomembranes. 2019; 1861: 418\u2013430.","DOI":"10.1016\/j.bbamem.2018.11.006"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013; 73: 919\u2013934.","DOI":"10.1007\/s40265-013-0069-4"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy. 1996; 42: 308\u2013314.","DOI":"10.1159\/000239459"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Jaggavarapu S, Burd EM, Weiss DS. Micafungin and amphotericin B synergy against Candida auris. The Lancet. Microbe. 2020; 1: e314\u2013e315.","DOI":"10.1016\/S2666-5247(20)30194-4"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Thompson GR, Huang H, Feng S, Yu Y, Soriano A, Cornely OA, et al. Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study. Open Forum Infectious Diseases. 2025; 12: ofaf555.","DOI":"10.1093\/ofid\/ofaf555"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. The Journal of Antimicrobial Chemotherapy. 2016; 71: 2868\u20132873.","DOI":"10.1093\/jac\/dkw214"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"El Ayoubi LW, Allaw F, Moussa E, Kanj SS. Ibrexafungerp: A narrative overview. Current Research in Microbial Sciences. 2024; 6: 100245.","DOI":"10.1016\/j.crmicr.2024.100245"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Spec A, Pullman J, Thompson GR, Powderly WG, Tobin EH, Vazquez J, et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. The Journal of Antimicrobial Chemotherapy. 2019; 74: 3056\u20133062.","DOI":"10.1093\/jac\/dkz277"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Ceballos-Garzon A, Lebrat J, Holzapfel M, Josa DF, Welsch J, Mercer D. Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. Antimicrobial Agents and Chemotherapy. 2025; 69: e0013725.","DOI":"10.1128\/aac.00137-25"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Gamal A, Chu S, McCormick TS, Borroto-Esoda K, Angulo D, Ghannoum MA. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata. Frontiers in Cellular and Infection Microbiology. 2021; 11: 642358.","DOI":"10.3389\/fcimb.2021.642358"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Mesquida A, D\u00edaz-Garc\u00eda J, S\u00e1nchez-Carrillo C, Mu\u00f1oz P, Escribano P, Guinea J. In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method. Clinical Microbiology and Infection: the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022; 28: 140.e1\u2013140.e4.","DOI":"10.1016\/j.cmi.2021.09.030"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Ordaya EE, Clement J, Vergidis P. The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective. Mycopathologia. 2023; 188: 937\u2013948.","DOI":"10.1007\/s11046-023-00759-5"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021; 81: 1703\u20131729.","DOI":"10.1007\/s40265-021-01611-0"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Fr\u00f3is-Martins R, Martinez de San Vicente K, Maufrais C, Mertens S, Sertour N, Sitterl\u00e9 E, et al. IL-17-mediated antifungal immunity restricts Candida albicans pathogenicity in the oral cavity. Nature Microbiology. 2026; 11: 111\u2013124.","DOI":"10.1038\/s41564-025-02198-y"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Jiang L, Fang M, Tao R, Yong X, Wu T. Recombinant human interleukin 17A enhances the anti-Candida effect of human oral mucosal epithelial cells by inhibiting Candida albicans growth and inducing antimicrobial peptides secretion. Journal of Oral Pathology & Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2020; 49: 320\u2013327.","DOI":"10.1111\/jop.12889"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Kaur G, Chawla S, Kumar P, Singh R. Advancing Vaccine Strategies against Candida Infections: Exploring New Frontiers. Vaccines. 2023; 11: 1658.","DOI":"10.3390\/vaccines11111658"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Edwards JE Jr, Schwartz MM, Schmidt CS, Sobel JD, Nyirjesy P, Schodel F, et al. A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2018; 66: 1928\u20131936.","DOI":"10.1093\/cid\/ciy185"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Wu Y, Hu S, Wu C, Gu F, Yang Y. Probiotics: Potential Novel Therapeutics Against Fungal Infections. Frontiers in Cellular and Infection Microbiology. 2022; 11: 793419.","DOI":"10.3389\/fcimb.2021.793419"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Wright E, Valand N, Venkatraman Girija U. Harnessing Probiotics to Combat Candidiasis: Mechanisms, Evidence, and Future Directions. Journal of Fungi (Basel, Switzerland). 2025; 11: 779.","DOI":"10.3390\/jof11110779"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Le\u00f3n-Buitimea A, Garza-Cervantes JA, Gallegos-Alvarado DY, Osorio-Concepci\u00f3n M, Morones-Ram\u00edrez JR. Nanomaterial-Based Antifungal Therapies to Combat Fungal Diseases Aspergillosis, Coccidioidomycosis, Mucormycosis, and Candidiasis. Pathogens (Basel, Switzerland). 2021; 10: 1303.","DOI":"10.3390\/pathogens10101303"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Vincekovi\u0107 M, \u017divkovi\u0107 Genzi\u0107 L, Jal\u0161enjak N, Kaliterna J, Rezi\u0107 Me\u0161trovi\u0107 I, Majdak M, et al. Antifungal Activity of Ag and ZnO Nanoparticles Co-Loaded in Zinc\u2013Alginate Microparticles. Sustainability. 2025; 17: 11374.","DOI":"10.3390\/su172411374"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Oso TA, Adebayo UO, Okesanya OJ, Chukwu CN, Ayelaagbe OB, Obadeyi KB, et al. Nanotechnology-driven antifungal strategies: A systematic review of mechanisms, therapeutic efficacy, and translational barriers in combating drug-resistant fungal infections. Next Nanotechnology. 2025; 8: 100290.","DOI":"10.1016\/j.nxnano.2025.100290"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/8\/10.31083\/FBL50241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:35:42Z","timestamp":1788438942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/8\/10.31083\/FBL50241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02118-0"],"URL":"https:\/\/doi.org\/10.31083\/fbl50241","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"50241"}}